Cancers & treatments·Regimen libraryNeoadjuvant

CROSS chemoradiation

Checked 2026-09-09

Resectable oesophageal or junctional cancer (T1N1 or T2-3N0-1), before surgery

One cycle

weekly × 5 · about 5 weeks in total

7-day cycle × 5 weekly doses with 41.4 Gy in 23 fractions (about 5 weeks)IntravenousRadiotherapy

Components

Drug	Dose	Route	Days
Carboplatin Cytotoxic chemotherapy (platinum)	AUC 2	IV	D1
Paclitaxel Cytotoxic chemotherapy (taxane)	50 mg/m²	IV	D1
Radiotherapy	1.8 Gy per fraction, 5 days a week	Radiotherapy	D1-5

Cycles

5 weekly doses with 41.4 Gy in 23 fractions

7-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

CheckMate 577: adjuvant nivolumab for one year if residual disease at surgery.

Used in

Oesophageal cancer Gastric & gastro-oesophageal junction cancer

Trials

CROSS CheckMate 577

Products

CarboplatinPaclitaxel / nab-paclitaxel

Source

CROSS, NEJM 2012

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.